Related Experiment Videos
Enteric-coated layered double hydroxides as a controlled release drug delivery system
Bingxin Li1, Jing He, David G Evans
1Ministry of Education Key Laboratory of Science and Technology of Controllable Chemical Reactions, Box 98, Beijing University of Chemical Technology, Beijing 100029, PR China.
International Journal of Pharmaceutics
|November 16, 2004
Summary
Layered double hydroxides (LDHs) were coated with enteric polymers to create a core-shell drug delivery system. This composite material enables controlled release of Fenbufen throughout the gastrointestinal tract.
Area of Science:
- Materials Science
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Layered double hydroxides (LDHs) are biocompatible materials suitable for host-guest supramolecular structures.
- The basicity of LDHs limits their application in acidic environments like the stomach.
- Developing pH-responsive drug delivery systems is crucial for effective gastrointestinal drug delivery.
Purpose of the Study:
- To develop a core-shell drug delivery system using LDHs and enteric polymers.
- To overcome the limitations of basic LDHs in acidic gastrointestinal conditions.
- To achieve controlled release of Fenbufen in a simulated gastrointestinal environment.
Main Methods:
- Fenbufen was intercalated into LDHs to form the core material.
- The Fenbufen-LDH core was coated with enteric polymers (Eudragit S 100 or Eudragit L 100) to create a shell.
- In vitro studies were conducted to model drug release throughout the gastrointestinal tract.
Main Results:
- A core-shell composite material was successfully synthesized.
- The composite material demonstrated controlled drug release properties.
- The enteric coating protected the drug in simulated gastric conditions and facilitated release in intestinal conditions.
Conclusions:
- The core-shell LDH-based system offers a promising approach for pH-responsive drug delivery.
- Coating LDHs with enteric polymers enhances their applicability as drug delivery vehicles.
- This strategy enables targeted and controlled release of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.